Trial Profile

A phase 3 study of CMIO-OLNZ in Chemotherapy induced nausea and vomiting

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olanzapine (Primary)
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use
Sponsors Starton Therapeutics

Most Recent Events

26 Dec 2019 New trial record
18 Dec 2019 According to an ChemioCare Media Release, based on the results from the previous comparative bioavailability (BA) study the product is now clinically ready to advance to its Phase 3 clinical study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com